Humana Expands Medicare Advantage Coverage for AngioDynamics' NanoKnife IRE System
Event summary
- Humana updated its Medicare Advantage coverage policy to include AngioDynamics' NanoKnife IRE system for intermediate-risk prostate cancer and certain liver tumors, effective October 1, 2026.
- The policy aligns with LCD L40205 criteria, following earlier reimbursement milestones including Category I CPT codes and Palmetto GBA’s final LCD.
- Humana, with approximately 7 million Medicare Advantage members, will apply the LCD criteria as its medical necessity standard.
- NanoKnife IRE uses irreversible electroporation to ablate targeted cells without thermal energy, approved for prostate and liver cancer treatments.
The big picture
Humana’s policy update represents a significant step in expanding access to AngioDynamics' NanoKnife IRE system, following key reimbursement milestones. This aligns with broader industry trends toward non-thermal ablation technologies and underscores the strategic importance of payer coverage in medical device adoption. With Humana’s large Medicare Advantage membership, the policy could enhance market penetration and competitive positioning for AngioDynamics in the cancer treatment space.
What we're watching
- Market Penetration
- How Humana’s coverage expansion will affect adoption rates of NanoKnife IRE among eligible patients.
- Reimbursement Dynamics
- Whether the consistent coverage framework under LCD L40205 will drive broader insurer adoption.
- Competitive Positioning
- The pace at which AngioDynamics can leverage this milestone to differentiate NanoKnife IRE in the cancer treatment market.
Related topics